Clinical Trial Update: Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study [Phase 2]

View source ↗

Summary

Phase 2 trial update shows efficacy and safety of deferasirox in patients with iron overload and non-transfusion-dependent thalassemia, including a one-year ope…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-transfusion-dependent Thalassemia

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-transfusion Dependent Thalassemia | Phase 2 | Status: COMPLETED | Results posted: 2012-09-25